In this video, Dr. Mimoun Ayoub, Senior VP, Global Commercial Head of Peptides & Oligonucleotides, highlights the critical elements needed to ensure a resilient CDMO supply for complex peptide APIs across the entire development and manufacturing lifecycle, from drug substance to finished drug product.
Peptides are inherently complex molecules that require highly specialized technologies and deep expertise. With the rapid growth of the GLP-1 market, scalable capacity – particularly in early-stage development – has become essential to support accelerating demand.
CordenPharma addresses this need with dedicated early clinical phase I-II peptide development capabilities at our CordenPharma Frankfurt (DE) site, helping customers advance to clinical stages more quickly.
Through our PepCellerate™ First-in-Human (FIH) offering, customers benefit from true end-to-end support that combines clinical drug substance manufacturing in Frankfurt with forward-integrated drug product capabilities. These include robust injectable manufacturing in CordenPharma Caponago (IT) and innovative oral solid dose peptide delivery capacity in CordenPharma Plankstadt (DE), enabling streamlined development with accelerated timelines for peptide-based FIH clinical trials.
For commercial scale-up, CordenPharma ensures continuity from development of grams to large-scale metric tons in our CordenPharma Colorado (USA) facility, while CordenPharma Liestal (CH) supports late-stage, mid-scale peptide production, alongside lipid and small molecule capabilities.
Together, this global network of specialized facilities creates a resilient, flexible peptide supply chain, supporting customers with seamless outsourcing for their peptide-based therapeutic drug development.
Are you a Boston-based peptide innovator? Learn more and register for our upcoming
Peptides Summit 2026 I Sept 23rd I Swissnex Boston.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.